226 related articles for article (PubMed ID: 37874541)
1. M2pep-Modified Cyclodextrin-siRNA Nanoparticles Modulate the Immunosuppressive Tumor Microenvironment for Prostate Cancer Therapy.
Sun Y; Cronin MF; Mendonça MCP; Guo J; O'Driscoll CM
Mol Pharm; 2023 Nov; 20(11):5921-5936. PubMed ID: 37874541
[TBL] [Abstract][Full Text] [Related]
2. Sialic acid-targeted cyclodextrin-based nanoparticles deliver CSF-1R siRNA and reprogram tumour-associated macrophages for immunotherapy of prostate cancer.
Sun Y; Cronin MF; Mendonça MCP; Guo J; O'Driscoll CM
Eur J Pharm Sci; 2023 Jun; 185():106427. PubMed ID: 36948408
[TBL] [Abstract][Full Text] [Related]
3. Molecular-Targeted Immunotherapeutic Strategy for Melanoma via Dual-Targeting Nanoparticles Delivering Small Interfering RNA to Tumor-Associated Macrophages.
Qian Y; Qiao S; Dai Y; Xu G; Dai B; Lu L; Yu X; Luo Q; Zhang Z
ACS Nano; 2017 Sep; 11(9):9536-9549. PubMed ID: 28858473
[TBL] [Abstract][Full Text] [Related]
4. Remodeling tumor immune microenvironment via targeted blockade of PI3K-γ and CSF-1/CSF-1R pathways in tumor associated macrophages for pancreatic cancer therapy.
Li M; Li M; Yang Y; Liu Y; Xie H; Yu Q; Tian L; Tang X; Ren K; Li J; Zhang Z; He Q
J Control Release; 2020 May; 321():23-35. PubMed ID: 32035193
[TBL] [Abstract][Full Text] [Related]
5. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes.
Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L
Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579
[No Abstract] [Full Text] [Related]
6. Synthesis and evaluation of multivalent M2pep peptides for targeting alternatively activated M2 macrophages.
Ngambenjawong C; Cieslewicz M; Schellinger JG; Pun SH
J Control Release; 2016 Feb; 224():103-111. PubMed ID: 26772876
[TBL] [Abstract][Full Text] [Related]
7. Targeted ferritin nanoparticle encapsulating CpG oligodeoxynucleotides induces tumor-associated macrophage M2 phenotype polarization into M1 phenotype and inhibits tumor growth.
Shan H; Dou W; Zhang Y; Qi M
Nanoscale; 2020 Nov; 12(43):22268-22280. PubMed ID: 33146206
[TBL] [Abstract][Full Text] [Related]
8. Surface Modification of Polymeric Nanoparticles with M2pep Peptide for Drug Delivery to Tumor-Associated Macrophages.
Pang L; Pei Y; Uzunalli G; Hyun H; Lyle LT; Yeo Y
Pharm Res; 2019 Mar; 36(4):65. PubMed ID: 30859335
[TBL] [Abstract][Full Text] [Related]
9. Tumor microenvironment remodeling via targeted depletion of M2-like tumor-associated macrophages for cancer immunotherapy.
Cao Y; Qiao B; Chen Q; Xie Z; Dou X; Xu L; Ran H; Zhang L; Wang Z
Acta Biomater; 2023 Apr; 160():239-251. PubMed ID: 36774974
[TBL] [Abstract][Full Text] [Related]
10. Pulmonary administration of a CSF-1R inhibitor alters the balance of tumor-associated macrophages and supports first-line chemotherapy in a lung cancer model.
Zhang H; Almuqbil RM; Alhudaithi SS; Sunbul FS; da Rocha SRP
Int J Pharm; 2021 Apr; 598():120350. PubMed ID: 33545279
[TBL] [Abstract][Full Text] [Related]
11. Bio-Responsive nanoparticle for tumor targeting and enhanced photo-immunotherapy.
Tian D; Qin F; Zhao H; Zhang C; Wang H; Liu N; Ai Y
Colloids Surf B Biointerfaces; 2021 Jun; 202():111681. PubMed ID: 33714187
[TBL] [Abstract][Full Text] [Related]
12. Targeting and repolarizing M2-like tumor-associated macrophage-mediated MR imaging and tumor immunotherapy by biomimetic nanoparticles.
Chong L; Jiang YW; Wang D; Chang P; Xu K; Li J
J Nanobiotechnology; 2023 Oct; 21(1):401. PubMed ID: 37907987
[TBL] [Abstract][Full Text] [Related]
13. Reprogramming tumor-associated macrophages by a dually targeted milk exosome system as a potent monotherapy for cancer.
Chen Y; Gong L; Cao Y; Liu Z; Wang Y; Cheng H; Feng Y; Yao S; Yin Y; Wu Z; Huang Z
J Control Release; 2024 Feb; 366():395-409. PubMed ID: 38184235
[TBL] [Abstract][Full Text] [Related]
14. Rational combination of an immune checkpoint inhibitor with CSF1R inhibitor-loaded nanoparticle enhances anticancer efficacy.
Ramesh A; Malik V; Ranjani HA; Smith H; Kulkarni AA
Drug Deliv Transl Res; 2021 Dec; 11(6):2317-2327. PubMed ID: 34365577
[TBL] [Abstract][Full Text] [Related]
15. Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells.
Song Y; Tang C; Yin C
Biomaterials; 2018 Dec; 185():117-132. PubMed ID: 30241030
[TBL] [Abstract][Full Text] [Related]
16. Tumor-Microenvironment-Activatable Nanoparticle Mediating Immunogene Therapy and M2 Macrophage-Targeted Inhibitor for Synergistic Cancer Immunotherapy.
Hu Y; Nie W; Lyu L; Zhang X; Wang W; Zhang Y; He S; Guo A; Liu F; Wang B; Qian Z; Gao X
ACS Nano; 2024 Jan; 18(4):3295-3312. PubMed ID: 38252684
[TBL] [Abstract][Full Text] [Related]
17. Serum Stability and Affinity Optimization of an M2 Macrophage-Targeting Peptide (M2pep).
Ngambenjawong C; Gustafson HH; Pineda JM; Kacherovsky NA; Cieslewicz M; Pun SH
Theranostics; 2016; 6(9):1403-14. PubMed ID: 27375788
[TBL] [Abstract][Full Text] [Related]
18. Blocking LTB
Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C
Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900
[TBL] [Abstract][Full Text] [Related]
19. d-lactate modulates M2 tumor-associated macrophages and remodels immunosuppressive tumor microenvironment for hepatocellular carcinoma.
Han S; Bao X; Zou Y; Wang L; Li Y; Yang L; Liao A; Zhang X; Jiang X; Liang D; Dai Y; Zheng QC; Yu Z; Guo J
Sci Adv; 2023 Jul; 9(29):eadg2697. PubMed ID: 37467325
[TBL] [Abstract][Full Text] [Related]
20. The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment.
Yang M; Li J; Gu P; Fan X
Bioact Mater; 2021 Jul; 6(7):1973-1987. PubMed ID: 33426371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
